Targeting Molecular Collagen Defects from the Initiation of Knee Osteoarthritis

Kui Huang,Rongmao Qiu,Yijie Fang,Dantian Zhu,Xiaojing Li,Zhongyang Lv,Taoyu Jia,Yuxiang Fei,Daoning Zhou,Wenjun Wu,Yongjie Huang,Suwen Zhao,Yongqiao Zhu,Shaolin Li,Dongquan Shi,Yang Li

DOI: https://doi.org/10.1101/2024.06.13.24308739

2024-08-12

Abstract:Knee osteoarthritis (OA) is the most prevalent degenerative joint disease. When morphological changes become apparent on radiographs, no approved treatment can reverse the disease process. Early diagnosis is an unmet need demanding new molecular and imaging biomarkers to define OA from the earliest stages. In this context, we focus on collagen, the most basic building block of all joint tissues, and interrogate how OA development affects collagen's molecular folding, a previously underexplored area. Here, through whole-joint mapping with a peptide that recognizes unfolded collagen molecules, we report the discovery of collagen denaturation in cartilage before proteolysis and major histopathological degeneration in animal models and patients. Mechanistically, we reveal that such molecular collagen defects can be driven by mechanical overloading without collagenase degradation and are intimately associated with glycosaminoglycan loss. We showcase the advantages of using collagen denaturation as an early-stage OA hallmark for in vivo therapeutic evaluation and molecular magnetic resonance imaging (MRI) of subtle joint defects that are challenging to detect with conventional morphology-based MRI. These results highlight biomolecular integrity as a crucial dimension for characterizing joint degeneration and a molecular foundation for diagnosing early-stage OA and beyond.

Orthopedics

What problem does this paper attempt to address?

This paper attempts to address the issue of early diagnosis of knee osteoarthritis (OA). Specifically, the researchers focused on changes in collagen molecules during the early stages of OA, particularly the denaturation of collagen molecules, which is an area that has not been fully explored before. By developing a peptide (CHP) that can recognize denatured collagen molecules, the researchers found that collagen denaturation occurs before cartilage proteolysis and major histopathological degradation in both animal models and patients. Additionally, they revealed that this collagen molecular defect can be caused by mechanical overload without the need for collagenase degradation and is closely associated with the loss of glycosaminoglycans (GAG).

The main objectives of the study include:
1. **Early Diagnosis**: Achieving early diagnosis of OA by detecting collagen denaturation.
2. **Mechanism Study**: Investigating how mechanical overload and GAG loss lead to collagen denaturation.
3. **Therapeutic Evaluation**: Using collagen denaturation as a marker for early OA to evaluate the effectiveness of different treatments.
4. **Imaging Technology**: Developing new molecular magnetic resonance imaging (MRI) contrast agents to non-invasively detect early joint defects.

These research findings not only help to understand the early pathological processes of OA but also provide an important foundation for developing new early diagnosis and treatment methods.